NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research

        • Research Overview
        • Clinical Research Facility
        • Health Economics
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient & Public Involvement
    • Getting involved with research
    • Welcome Guide
    • Oxford BRC PPIE team
    • View and register for involvement opportunities
    • Patient & Public Groups
    • Patient and Public Involvement Advisory Group
    • Diversity in Research Group
    • PPI Researcher Guidance
    • PPIE Leads / Groups
    • Reporting PPIE
    • Post a PPIE opportunity
    • Case Studies
    • Patient and Public Involvement and Engagement (PPIE) Strategy
    • PPIE News
    • Public events
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > COVID-19 > Higher risk of blood clots in COVID-19 outpatients, largely reduced after vaccination

Higher risk of blood clots in COVID-19 outpatients, largely reduced after vaccination

22 August 2022 · Listed under COVID-19, Gene and Cell Therapy, Translational Data Science

Researchers supported by the NIHR Oxford Biomedical Research Centre (BRC) have studied the link between people diagnosed with COVID-19 as outpatients and the short-term risk of developing blood clots, and the clinical and genetic risk factors that predispose them to developing post–COVID-19 thrombosis.

Decorative illustration showing blood clots and COVID-19
Kateryna Kon/Shutterstock.com

Ambulatory COVID-19 patients (those diagnosed as outpatients) face an increased risk of venal thrombosis (blood clot in a vein) than the general population not affected by COVID-19, according to a new study by University of Oxford researchers.

But the researchers from the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) found that the risk was greatly reduced in fully vaccinated people with breakthrough infection.

Published in JAMA Internal Medicine, the retrospective, population-based cohort study examined the records of more than 400,000 participants from the UK Biobank. Some 18,818 were infected with SARS-CoV-2, identified by a positive PCR test in community settings. These were matched against 93,179 uninfected participants according to age, gender and a series of clinical features.

Frank Xie, lead author and research assistant in pharmaco-epidemiology at NDORMS, said: “Numerous hospital-based studies have demonstrated VTE (venous thromboembolism, or blood clots) in patients with severe COVID-19 who have been admitted for treatment. This was one of the first studies into ambulatory patients with the virus, and we’ve found that there is a substantially increased risk of VTE among this cohort of middle age and older patients.”

Other clinical risk factors include older age, being male, and obesity.

The team also identified genetic factors that predisposed patients to VTE. Those who carry the Factor V Leiden genetic mutation – which can result in an increased tendency to form abnormal blood clots – had an additional double risk of post–COVID-19 VTE compared with those without the mutation. This is equivalent to the excess risk associated with being ten years older,

“We did, however, find that the risk was significantly decreased for individuals who had been fully vaccinated,” said Frank. “Reinforcing the need for vaccinations, these findings may help to turn the tide of vaccine hesitancy and restrictions on their use. It could also help healthcare providers re-evaluate how they attentively prioritise treatments such as prophylaxis for milder ambulatory COVID-19 patients to mitigate the risks of VTE.”

← Moderate drinking linked to brain changes and cognitive decline
Study develops radiotranscriptomic AI analysis to enable virtual heart biopsies →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2023 NIHR Oxford Biomedical Research Centre